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SHERLEY V. SEBELIUS: A CALL TO CONGRESS TO EXPLICITLY
SUPPORT MEDICAL RESEARCH ON HUMAN EMBRYONIC STEM
CELLS
Layla Cummings'
Progressive biomedical research is the key to developing new
and effective treatments for many of the diseases and conditions
that afflict our society. The scientific community is in agreement
that human embryonic stem cell research is afield that holds great
promise. The recent federal district court opinion in Sherley v.
Sebelius threatens to derail the progress of science and the hope of
millions by denying federal funding of this research based on an
appropriations rider known as the Dickey-Wicker Amendment.
While the rider's plain language bans federal funding of any
research that creates or destroys embryos, it has been accepted for
over a decade that the government may fund research on stem cell
lines that are obtained through private funding. With an uncertain
outcome pending in the Court ofAppeals, it will be argued that the
Dickey-Wicker Amendment should be amended or repealed to give
effect to the longstanding practice by the National Institutes of
Health of funding human embryonic stem cell research within
ethical guidelines. Furthermore, Congress should make it a
priority to pass the Stem Cell Research Advancement Act in order
to explicitly support the efforts of scientists working with human
embryonic stem cells to develop groundbreaking medical
advances.
I. INTRODUCTION
Embryonic stem cell research has been a divisive political and
social issue since its inception. It provides hope of progressive
new treatments to the millions suffering from devastating medical
conditions, such as diabetes, heart disease, vision and hearing loss,
77
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and spinal cord injuries.! Unfortunately, since embryonic stem cell
research involves the destruction of human embryos, it also stirs
intense debate mainly focused on the moral status of days old
embryos. 2 In late August of 2010, a federal district court judge
sent the medical research community into a panic by declaring that
federal funding of embryonic stem cell research is contrary to
federal law. In Sherley v. Sebelius, Judge Royce Lamberth relies
on an appropriations rider known as the Dickey-Wicker
Amendment ("Amendment")' to strike down new guidelines
developed by the National Institutes of Health ("NIH"). These
guidelines were designed to increase the quantity of embryonic
stem cell lines available for medical research purposes.
The technique to isolate and grow stem cells from human
embryos was first perfected in 1998 by researchers at the
University of Wisconsin.' In the decade since the scientific
breakthrough was made, the issue has garnered attention from
conservatives and liberals alike. The first federal funds to go
towards human embryonic stem cell research were approved by
President George W. Bush, albeit with significant restrictions.'
Under President Obama, support for embryonic stem cell research
was to be expanded by an executive order that would lift the
J.D. Candidate, University of North Carolina School of Law, 2012.
1 Stem Cell Information: Stem Cell Basics, NAT'L INSTS. HEALTH, 8,
http://stemcells.nih.gov/staticresources/info/basics/SCprimer2009.pdf (last
modified Apr. 28, 2010).
2James F. Childress, Ph.D., An Ethical Defense of Federal Funding for
Human Embryonic Stem Cell Research, 2 YALE J. HEALTH POL'Y, L. & ETHICS
157, 160 (2001).
3 Sherley v. Sebelius, 704 F. Supp. 2d 63, 73 (D.D.C. 2010).
4 See Omnibus Appropriations Act 2009, Pub. L. No. 111-8, § 509(a)(2), 123
Stat. 524, 803 (2009); See also Balanced Budget Downpayment Act, Pub. L. No.
104-99, § 128, 110 Stat. 26, 34 (1996).
National Institutes of Health Guidelines for Human Stem Cell Research, 74
Fed. Reg. 32170 (July 7, 2009).
See Stem Cell Information: Frequently Asked Questions, NAT'L INSTS.
HEALTH, http://stemcells.nih.gov/info/faqs (last modified Aug. 2, 2010).
Exec. Order No. 13,435, 3 C.F.R. 222 (2007).
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restrictions put in place by President Bush.' Despite a change in
executive policy, the district court decision in Sherley v. Sebelius
demonstrates that President Obama may not be able to expand
embryonic stem cell research without the support of Congress.
Part II of this Recent Development briefly discusses the current
state of stem cell research and sets the foundation for the argument
that embryonic stem research should continue as a means of
ultimately providing effective treatment to life-threatening
conditions and diseases. Part III discusses the regulatory
framework surrounding stem cell research in the United States, the
holding reached in Sherley v. Sebelius, and the rationale behind the
decision. Part IV recommends that Congress act to amend or
repeal the Dickey-Wicker Amendment as well as pass legislation
codifying President Obama's executive order, which called for the
expansion of stem cell research within a responsible ethical
framework.9
11. THE BASICS OF STEM CELL RESEARCH
A. What Are Stem Cells?
Stem cells are important for research purposes because, unlike
other cells, they are undifferentiated. This means that they have
yet to transform into the many different types of cells in the body.o
There are three basic types of human stem cells: 1) embryonic
stem cells ("hESCs"); 2) adult stem cells ("ASCs"); and 3) induced
pluripotent stem cells ("iPSCs")." Human embryonic stem cells
are typically derived from pre-implantation stage embryosl2 and are
pluripotent, meaning they have the ability to divide into almost any
' President Obama fulfilled his promises to expand the scope of federal
funding of stem cell research with an executive order issued in 2009, during his
first year in office. See Exec. Order No. 13,505, 74 Fed. Reg. 10,667 (2009).
9 Id
10 Stem Cell Information: Frequently Asked Questions, supra note 6. Stem
cells are undifferentiated cells that have yet to acquire a specialized function.
Id
i See Stem Cell Information: Stem Cell Basics, supra note 1, at 2.
12 These embryos are usually the leftover embryos from in vitro fertilization
procedures that would have been discarded otherwise. See id at 8.
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type of cell in the body.13 Pluripotent cells provide a unique
glimpse into the study of cell development and are a potential
source for new replacement cells and tissues to be used in medical
treatments.14 Adult stem cells are cells found in organs and tissues
and are multipotent, meaning they are further differentiated than
hESCs but they can still be specialized into a few different cell
types." The area of the body where the particular adult stem cell
originated (i.e. the heart, bone marrow, blood) generally limits the
research value of ASCs.16 Research on ASCs has been conducted
since the 1950s and is accepted as uncontroversial because it
involves adult donors, not embryos.1  The third type of stem cell,
induced pluripotent stem cells, are adult cells that have been
"genetically reprogrammed to an embryonic stem cell-like state."
Research on human iSPCs began in late 2007 and is a promising
new area of research that may lead to the same type of potential for
medical treatments as hESCs.' 9
B. The Significance ofHuman Embryonic Stem Cell Research
Currently, federal funding supports all three types of stem cell
research.20 There have been policy arguments made that question
the necessity of human embryonic stem cell research when adult
stem cell research is successful and induced pluripotent stem cell
research may provide similar benefits. However, an argument in
13 Stem Cell Information: Frequently Asked Questions, supra note 6
("Pluripotent stem cells can give rise to any type of cell in the body except those
needed to support and develop a fetus in the womb.")14 d
15 id.
1 Stem Cell Information: Stem Cell Basics, supra note 1, at 4.
7 See Stephen R. Latham, The Once and Future Debate on Human
Embryonic Stem Cell Research, 9 YALE J. HEALTH POL'Y L. & ETHICS 483, 485
(2009) ("Adult stem cell research (and, for the most part, embryonic stem cell
research conducted in laboratory animals) has been fairly uncontroversial.").
1s Stem Cell Information: Frequently Asked Questions, supra note 6.
19 Stem Cell Information: Stem Cell Basics, supra note 1, at 13-14.
20 The Promise of Human Embryonic Stem Cell Research: Hearing on the
Promise of Embryonic Stem Cell Research before S. Subcomm. on Labor,
Health and Human Services, Education, and Related Agencies of the S. Comm.
on Appropriations, 111th Cong. 4-5 (2010) [hereinafter Hearing] (statement of
Dr. Francis Collins, Director, National Institutes of Health).
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favor of abandoning human embryonic stem cell research for adult
stem cell and induced pluripotent stem cell research is
shortsighted. 21 The reasoning against using exclusively adult stem
cells to conduct such research is simple: as multipotent cells,
ASCs have limited utility.2 2 Adult stem cells do not have the
flexibility to turn into almost any of the cells of the body, as hESCs
and iPSCs can when manipulated by researchers. 23 Additionally,
hESCs are capable of "long-term self renewal," 24 allowing them to
continue dividing without becoming differentiated for months or
even years, whereas most adult stem cells cannot perform this
function. 25  Long-term self-renewal allows researchers to
experiment on these particular lines of cells, which will help them
understand more and gain an understanding of the cellular
regulatory process, which could prove valuable for treatment
purposes.26
The abandonment of hESC research may also be premature
because induced pluripotent stem cell research is in its infancy and
human embryonic stem cells are still the "gold standard."7 With
only a few years of research completed on iPSCs, the research on
hESCs must continue in order to develop meaningful comparisons
between the two types of cells and their potential benefits to
medical research.28 In the meantime, the medical significance of
this research demands that we "simultaneously pursue all lines of
research." 29 Human embryonic stem cells provide a novel way to
conduct early stage screening for new drugs and "may hold the
21 id.
22 id.
23 Stem Cell Information: Stem Cell Basics, supra note 1, at 8.
24 Id. at 3, 22.
25 [d
26 Id. at 3.
27 Hearing, supra note 20, at 5 (statement of Dr. Francis Collins, Director,
National Institutes of Health).
28 Stem Cell Information: Stem Cell Basics, supra note 1, at 13-14. iPSC
research is not yet a substitute for embryonic stem cell research. Latham, supra
note 17, at 492. Researchers are still discovering the mechanism behind
pluripotency and exploring the differences between iPS cells and hES cells. Id.
29 Stem Cell Information: Frequently Asked Questions, supra note 6.
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secrets to creating entirely new targeted clinical therapies."3o
Developments in the public and private sector, including the first
Food and Drug Administration ("FDA") approved trial involving
the use of hESCs, demonstrate that the need for hESCs in
biomedical research is, and will remain, of significant importance
for the foreseeable future.3 1
III. THE LAW AND EMBRYONIC STEM CELLS
A. A BriefHistory of the Dickey-Wicker Amendment
The Dickey-Wicker Amendment was first added to the
Balanced Budget Downpayment Act of 199632 and has been
reenacted without "substantial alteration" 33 every year since as part
of the Health and Human Services Appropriations bill.34 The
relevant language states that federal funding will not support:
(1) the creation of a human embryo or embryos for research purposes;
or
(2) research in which a human embryo or embryos are destroyed,
discarded, or knowingly subjected to risk of injury or death greater than
that allowed for research on fetuses in utero . . .
Simply put, federal agencies may not fund research that will result
in the creation or destruction of embryos. This section of the
30 Francis Collins, NIH Director's Response to Stem Cell Injunction, NAT'L
INSTS. HEALTH (Aug. 26, 2010), http://www.nih.gov/about/director/
08262010statement stemcellinj unction.htm.
31 Geron Receives FDA Clearance to Begin World's First Human Clinical
Trial of Embryonic Stem Cell-Based Therapy, GERON (Jan. 23, 2009),
http://www.geron.com/media/pressview.aspx?id 1148. Field Code Changed
32 Balanced Budget Downpayment Act of 1996, Pub. L. No. 104-99, 110 Stat.
26.
33 Sherley v. Sebelius, 704 F. Supp. 2d 63, 67 (D.D.C. 2010) (citing Omnibus
Appropriations Act 2009, Pub. L. No. 111-8, § 509(a)(2), 123 Stat. 524, 803
(2009)).
4 [d.
3 Omnibus Appropriations Act 2009, Pub. L. No. 111-8, § 509, 123 Stat. 524,
803 (2009). This section goes on to define a human embryo as "any organism,
not protected as a human subject under 45 C.F.R. § 46 as of the date of the
enactment of this Act, that is derived by fertilization, parthenogenesis, cloning,
or any other means from one or more human gametes or human diploid cells."
Id at § 509 (b).
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appropriations bill is known as an appropriations rider,3 ' and is
commonly used to limit the funding that federal agencies may use
for specific purposes.3 7 Limitation riders such as the Amendment
can be controversial because they do not involve the same review
process as substantive legislation passed by Congress that directly
bans agency action.38
Human stem cell research took off in earnest in 1998 when Dr.
James Thomson's method of isolating stem cells was developed.39
This development occurred two years after the Amendment was
signed into law.40 The Amendment has been passed every year
since 1996 without "substantial alteration"41 as part of the Health
and Human Services appropriations bill.42 Given the timeline,
proponents of hESC research will argue that the Amendment was
not passed with the specific intention of limiting hESC research.43
3 Ryan Fujikawa, Federal Funding of Human Embryonic Stem Cell
Research: An Institutional Examination, 78 S. CAL. L. REV. 1075, 1083 (2005).
This type of appropriations rider is known as a "limitation rider." Neal E.
Devins, Regulation of Government Agencies Through Limitation Riders, 1987
DUKE L.J. 456, 461 (1987) ("One of the most controversial and frequently used
devices of appropriations-based oversight of executive action is the limitation
rider.").
38 Id. at 458 ("The use of the appropriations process to accomplish substantive
objectives that have not been considered previously or that contravene
established statutory objectives may prevent the appropriate authorizing
committee from applying its expertise. Exacerbating this problem,
appropriations are often acted on quickly, providing little opportunity for
thoughtful deliberation of the issues raised by such measures.").
39 James Thomson et al., Embryonic Stem Cell Lines Derived from Human
Blastocysts, SCIENCE, Nov. 6, 1998, at 1145.
40 "Scientists have only been able to do experiments with human embryonic
stem cells (hESCs) since 1998, when a group led by Dr. James Thomson at the
University of Wisconsin developed a technique to isolate and grow the cells."
Stem Cell Information: Frequently Asked Questions, supra note 6.
41 Sherley v. Sebelius, 704 F. Supp. 2d 63, 67 (D.D.C. 2010) (citing Omnibus
Appropriations Act 2009, Pub. L. No. 111-8, § 509(a)(2), 123 Stat. 524, 803
(2009)).
42 Sherley, 704 F. Supp. 2d at 67.
43 In passing the Amendment, Congress was reacting to a 1994 NIH panel that
recommended funding for research on human embryos that would improve in
vitro fertilization techniques. Brief for Appellants at 11, Sherley v. Sebelius,
704 F. Supp. 2d 63, (D.C. Cir. 2010) (No. 10-5287) (citing NIH, Report of the
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However, opponents have a strong argument that the Amendment
was passed with the intention of regulating the use of federal funds
for research that was not yet in existence, but could involve human
embryos.44
The Amendment can be interpreted to ban all research activity
that will result in the destruction of human embryos.45 After stem
cells were first derived from embryos, a process that necessarily
destroys the embryo, 6 the NIH requested guidance from the U.S.
Department of Health and Human Services ("HHS") regarding
funding of embryonic stem research.47 In 1999, near the end of the
Clinton Administration, HHS legal counsel Harriet S. Rabb wrote
a memorandum on behalf of HHS, which concluded that the
Amendment did not ban the use of federal funds to conduct hESC
research.4 8 Ms. Rabb made a distinction between the use of human
embryos and the use of human embryonic stem cell lines for
research purposes:4 9
Pluripotent [embryonic] stem cells are not organisms and do not have
the capacity to develop into an organism that could perform all the life
functions of a human being. They are, rather, human cells that have the
potential to evolve into different types of cells such as blood cells or
insulin-producing cells .... Pluripotent stem cells do not have the
capacity to develop into a human being, even if transferred to a uterus
Human Embryonic Research Panel 75-76 (1994), available at
Jittp://bioethics.georgetown.edu/pcbe/reports/past commissions/index.html.
44 Hearing, supra note 20 (statement of Sen. Roger Wicker). Senator Wicker
was a coauthor of the Dickey-Wicker Amendment when he was a member of the
House of Representatives in 1995. Id. He testified at the most recent hearing on
stem cell research to support a ban on using federal funding for human
embryonic stem cell research. Id. Senator Wicker maintains that "the body of
evidence developed since 1995 has served only to strengthen the argument in
favor of Dickey-Wicker." Id
45 Judge Lamberth came to this conclusion when holding that the language of
the Dickey-Wicker Amendment is unambiguous. See Sherley, 704 F. Supp. 2d
at 71.
4 6 See id at 67.
47 Diane T. Duffy, Background and Legal Issues Related to Stem Cell
Research, ALMANAC OF POLICY ISSUES, http://www.policyalmanac.org/health/
archive/crs stem cell.shtml (last modified June 12, 2002).
48 id.
49 Id. (citing Memorandum from HHS Gen. Counsel Harriet Rabb to Harold
Varmus, Dir., NIH (Jan. 15, 1999)).
Field Code Changed
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.... Based on an analysis of the relevant law and scientific facts,
federally funded research that utilizes human pluripotent stem cells
would not be prohibited by the HHS appropriations law [Dickey-
Wicker Amendment] prohibiting human embryo research, because such
stem cells are not human embryos."o
With this interpretation of the law, it was assumed that the federal
government could legally fund research on embryonic stem cell
lines," as long as they did not actually fund derivation of the
original stem cells from the embryo.52
In 2001, President Bush issued an executive order seeking to
limit federal funding of embryonic stem cell research.3 Under the
new presidential policy, federal funds could be used to support
hESC research only on stem cell lines already in existence, which
precluded using federal funds on any new stem cell lines.54 While
President Bush's policy did indeed limit the "destruction" of
human embryos, it also impliedly adopted the interpretation of the
Dickey-Wicker Amendment set out by the Rabb memorandum,
making it legal for the federal government to spend taxpayer
dollars on research of hESC lines as long as that money did not go
specifically to the derivation of the stem cells."
50 Memorandum from HHS Gen. Counsel Harriet Rabb to Harold Varmus,
Dir., NIH (Jan. 15, 1999).51 The key distinction is that embryonic stem cell lines are technically
different from embryos. "A stem cell line is a family of constantly-dividing
cells, the product of a single parent group of stem cells. They are obtained from
human or animal tissues and can replicate for long periods of time in vitro."
Extended Definition: Stem Cell Line, WEBSTERS ONLINE DICTIONARY,
http://www.websters-online-dictionary.org/definitions/Stem+cell+line (last
visited Sept. 27, 2010).
52 See Gardiner Harriss & Sheryl Gay Stolberg, Stem Cell Ruling Will Be
Appealed, THE N.Y. TIMES (Aug. 24, 2010), http://www.nytimes.com/2010/
08/25/health/policy/25stem.html.
53 Exec. Order No. 13,435, 3 C.F.R. 222 (2008).
54 George W. Bush, Address to the Nation on Stem Cell Research From
Crawford, Texas, 37 WEEKLY COMP. PREs. Doc. 1149 (Aug. 9, 2001); see also
NIH Human Embryonic Stem Cell Registry Under Former President Bush (Aug.
9, 2001-Mar. 9, 2009), NAT'L INSTS. HEALTH, http://stemcells.nih.gov/research/
registry/eligibilitycriteria (last modified Mar. 9, 2009).
See Bush, supra note 54.
Field Code Changed
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On March 9, 2009, President Obama issued an executive order
that revoked the limitations to hESC research set out by the Bush
Administration. 6 The new policy called for additional hESC lines
to be introduced into the NIH stem cell registry and for the NIH to
issue new guidelines that would promote the use of stem cell lines
derived from excess embryos that would otherwise be discarded
from in vitro fertilization procedures. The new NIH Guidelines
for Human Stem Cell Research ("Guidelines") took effect on July
7, 2009." The Guidelines remained consistent with the standing
interpretation of the Dickey-Wicker Amendment: federal funding
would not go towards the actual derivation of embryos but would
fund research on hESC lines.5 9
At the time Obama's executive order was implemented,
Congress and the Executive Branch had been operating under the
Rabb interpretation of the Amendment for ten years.6 o The general
perception was that the federal government could fund research on
hESCs as long as the money did not go directly towards the
derivation process that would destroy the embryos. This settled
interpretation was brought into question when two scientists who
specialize in adult stem cell research challenged the new NIH
Guidelines.6
B. The Holding and Impact of Sherley v. Sebelius
On August 23, 2010, Judge Royce Lamberth of the Federal
District Court for the District of Columbia enjoined the NIH from
56 Exec. Order No. 13,505, 74 Fed. Reg. 10667 (Mar. 9, 2009).
57id.
58 NIH Guidelines for Human Stem Cell Research, 74 Fed. Reg. 32170 (July
7, 2009).
59 But see Sherley v. Sebelius, No. 09-1575 (D.C. Cir.), stay denied Aug. 31,
2010) ("The prior guidelines, of course, allowed research only on existing stem
cell lines, foreclosing additional destruction of embryos.").
60 Congress has continually passed the Amendment, even though they were
aware that the NIH and other institutions used federal monies to do research on
human embryonic stem cell lines.
6i Drs. James Sherley and Theresa Diescher are plaintiffs in the case who
conduct non-embryonic stem cell research and claim that funding of hESC
harms them. See Sherley v. Sebelius, 704 F. Supp. 2d 63 (D.D.C. 2010).
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implementing the new Guidelines,62 as authorized by Obama's
executive order entitled Removing Barriers to Responsible
Scientific Research Involving Human Stem Cells.3 Drs. James
Sherley and Theresa Deischer, Nightlight Christian Adoptions,
Embryos, prospective adoptive parents, and the Christian Medical
Association originally brought the suit to enjoin defendants from
implementing the Guidelines or otherwise funding research that
involves the destruction of hESCs.6 4 The district court dismissed
the suit on the basis that plaintiffs lacked standing.6 5 The Court of
Appeals reversed and remanded, finding that Drs. Sherley and
Deischer did have standing based on the competitor standing
doctrine."6 On remand, Judge Lamberth found in favor of the
plaintiffs and imposed a preliminary injunction blocking the NIH
from implementing the new Guidelines."
The holding reached by the district court prohibited the
implementation of the Guidelines on the basis that they violated
the plain language of the Dickey-Wicker Amendment." The
rationale for the decision follows a simple logical syllogism:
[Embryonic stem cell ("ESC")] research is clearly research in which an
embryo is destroyed. To conduct ESC research, ESCs must be derived
from an embryo. The process of deriving ESCs from an embryo results
in the destruction of the embryo. Thus, ESC research necessarily
depends upon the destruction of a human embryo.6 9
62 Guidelines, 74 Fed. Reg. at 32,170.
63 Sherley, 704 F. Supp. 2d at 73.
64 Sherley v. Sebelius, 686 F. Supp. 2d 1, 3 (D.D.C. 2009) rev'd in part, 610
F.3d 69 (D.C. Cir. 2010).
6 1Id. at 7.
66 Sherley v. Sebelius, 610 F.3d 69, 74 (D.C. Cir. 2010) (stating "[b]ecause
the Guidelines have intensified the competition for a share in a fixed amount of
money, the plaintiffs will have to invest more time and resources to craft a
successful grant application. That is an actual, here-and-now injury.").
67 Sherley v. Sebelius, 704 F. Supp. 2d 63, 73 (D.D.C. 2010).
68 Id. at 71 (holding if hESC research is "research in which a human embryo is
to be harmed or destroyed," the Guidelines violate the Dickey-Wicker
Amendment).
69 Sherley, 704 F. Supp. 2d at 71.
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Essentially, Judge Lamberth found the distinction between
research done on hESC lines and research that directly involves
deriving the cells from the embryo to be immaterial.70 He
discounted the Rabb interpretation of the word "embryo" because
it assumes the Dickey-Wicker Amendment is ambiguous.71 To the
contrary, Judge Lamberth found that the plain language of the
Dickey-Wicker Amendment is unambiguous and explicitly bans all
research involving the destruction of human embryos.7 2
The government filed an appeal along with a motion to stay the
preliminary injunction. After a denial from the district court, the
Court of Appeals for the District of Columbia granted the motion
and the injunction will be stayed until the appeal can be heard.74
The stay gives the NIH and other institutions that depend on
federal funding breathing room to continue critically important
biomedical research until the merits of the case can be heard on
appeal. However, it does not give scientists conducting long-term
research experiments any certainty regarding funding that must be
renewed every twelve months. This is especially troublesome in
light of the fact that most embryonic stem cell research is long-
term.75 It may also discourage younger scientists from applying for
new grants that involve the use of human embryonic stem cell
lines.76
IV. CONGRESS AND STEM CELL RESEARCH
70
71 Id. at 71-72.
72 Id. at 72.
7 Stem Cell Reseach [sic]: Government Files Appeal, Seeks Stay Order in
Case Halting Stem Cell Research Funding, Biotech Watch Online (BNA) (Sep.
1,2010).
74 Sherley v. Sebelius, No. 10-5287, (D.C. Cir. Sept. 10, 2010) (granting stay).
75 Embryonic stem cell research has been conducted since 1998 and it is only
recently that the first FDA approved trial has begun. See Geron Receives FDA
Clearance to Begin World's First Human Clinical Trial ofEmbryonic Stem Cell-
Based Therapy, GERON (Jan. 23, 2009),
http://www.geron.com/media/pressview.aspx?id 1148.
7 See Hearing, supra note 20, at 4 (statement of George Q. Daley, M.D.,
Ph.D.).
Field Code Changed
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A. The Intent of Congress
Judge Lamberth argued that the congressional intent outside
the text of the Dickey-Wicker Amendment is irrelevant because
the plain language of the Amendment is unambiguous.7
Nonetheless, Judge Lamberth noted that Congress does not support
the use of federal funds for hESC research because "Congress has
included the Dickey-Wicker Amendment in every appropriations
bill for Health and Human Services ("HHS") since 1996 without
substantive alteration."" The debate over the ambiguity, or lack of
ambiguity, in the language of the Dickey-Wicker Amendment is
likely to be a major issue on appeal.
On one hand, Congress has passed the Dickey-Wicker
Amendment every year since 1996 without making any attempt to
narrow its language, despite the knowledge that advances in stem
cell research involve the destruction of embryos in the initial phase
of the research process.7 9  On the other hand, it is clear that
Congress has been fully aware of the state of stem cell research
and has not taken action to reject the definition of "embryo" set by
the Clinton Administration and adopted by the NIH in 2000."
1 See Sherley v. Sebelius, 704 F. Supp. 2d 63, 70. Chevron deference refers
to a legal test that determines how much deference a court must grant to a
government agency's interpretation of a statute. If Congress speaks directly to
the issue, the agency must give effect to the intent of Congress and the courts
grant no deference to agency interpretation. The courts base their decision on
the clear intent of Congress. When Congress has used ambiguous language, the
courts grant deference to the agency's interpretation of the statute. See Chevron
U.S.A. Inc. v. Natural Res. Def. Council, Inc., 467 U.S. 837 (1984). The issue
for this court is whether or not Congress's intent is clear within the Dickey-
Wicker Amendment standing on its own. If it is clear, then that is the end of the
issue. If it is ambiguous, the court may grant deference to the interpretation
adopted by the NIH Guidelines.
71 Sherley, 704 F. Supp. 2d at 67-68 (citing Omnibus Appropriations Act
2009, Pub. L. No. 111-8, § 509, 123 Stat. 524, 803 (2009)).
79 The Senate Appropriations Subcommittee on Labor, Health, and Human
Services has held twenty-one hearings on embryonic stem cell research since
December of 1998. See Hearing, supra note 20 (statement of Sen. Thomas
Harkin).
' Id. Congress has acted with "full knowledge that HHS has been funding
hESC research since 2001." NIH Guidelines for Human Stem Cell Research, 74
Fed. Reg. 31,270, 32,173 (July 7, 2009).
Field Code Changed
12 N.C. J.L. & TECH. ON. 77,90
Stem Cell Research: Sherley v. Sebelius
Should congressional silence on this issue be seen as condoning or
rejecting the Rabb interpretation? Although debatable, there is
evidence that Congress has condoned the actions of the NIH. For
example, in its memorandum to the court in support of the motion
to stay the preliminary injunction, the government defendants
argue that Congress has endorsed the interpretation that a
distinction can be made between embryos and hESC lines:
Congress has done more than acquiesce in NIH's interpretation: it has
expressly endorsed the view that hESC research is not barred by the
Dickey-Wicker Amendment. In light of the endorsement by Congress
of that rational, long-standing interpretation-an endorsement that was
magnified by Congress's approval of the interpretation in the recent
passage of the 2010 appropriations for NilH-defendants respectfully
assert that their interpretation is consistent with ... congressional
intent.
If it is indeed clear that Congress implicitly supports
embryonic stem cell research, why has it exclusively relied on
executive orders to define the parameters of such research since
2001? There seem to be two reasons an embryonic stem cell
research bill has yet to become law: 1) two separate bills were
passed by Congress during the Bush Administration and both
subsequently vetoed, slowing momentum for further action;8 2 and
2) Congress did not feel it imperative to amend the Dickey-Wicker
Amendment when interpretation allowing human embryonic stem
" Memorandum in Support of Defendants' Emergency Motion to Stay the
Preliminary Injunction Pending Appeal and for Expedited Briefing and
Consideration at 2, Sherley v. Sebelius, 704 F. Supp. 2d 63 (D.D.C. 2010) (No.
1:09-cv-01575-RCL).
82 See The Stem Cell Research Enhancement Act of 2005, H.R. 810, 109th
Cong. (2006). See also The Stem Cell Research Enhancement Act of 2007, S. 5,
110th Cong. (2007). The Stem Cell Research Enhancement Acts of 2005 and
2007 were bills passed by Congress and subsequently vetoed by President Bush.
Both bills called for the support of human embryonic stem cell research,
regardless of the date in which the stem cells were derived from the embryo.
Additionally, both bills would have limited federal funding to the use of stem
cell lines derived from embryos that would otherwise be discarded from in vitro
fertilization clinics.
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cell research appeared to be settled by long-standing practice.83
Simply put, there has been a lack of political will to change the
status quo. Now that the standing interpretation has been brought
into question, it is the time for Congress to explicitly endorse the
federal funding of embryonic stem cell research through new
legislation. If Congress can successfully pass another bill
supporting hESC research, as it did with the Stem Cell
Enhancement Acts of 2005 and 2007, they can count on a different
outcome since it is likely that President Obama would support such
legislation.84
B. "Sand into the Engine of Discovery"
It is imperative that Congress changes the language of the
Dickey-Wicker Amendment while there is an appeal pending and
before the preliminary injunction can be reinstated. With the latest
advances, including the start of an FDA-approved trial using
hESCs,"5 it is more important than ever to secure funding for this
type of research. Francis Collins, Director of the NIH and a named
defendant in Sherley, stated in reference to the current state of
hESC research, "[lt]his is one of the most exciting areas of the
broad array of engines of discovery that NIH supports. This
decision has just poured sand into that engine of discovery.""
In order to reverse the negative consequences the district
court's decision has had on the scientific community, Congress
needs to amend or repeal the Dickey-Wicker Amendment. This
would give scientists the confidence and stability necessary to
pursue research that can potentially benefit those with currently
incurable conditions. The decision in Sherley rested on the
definition of the word "research" as definitively meaning "a
The NIH adopted the current interpretation of the Amendment in its
guidelines issued in 2000. NIH Guidelines for Research Using Human
Pluripotent Stem Cells, 65 Fed. Reg. 51,976, 51,979 (Aug. 25, 2000).
84 See Exec. Order No. 13,505, 74 Fed. Reg. 10,667 (Mar. 9, 2009).
85 See Geron Receives FDA Clearance to Begin World's First Human Clinical
Trial of Embryonic Stem Cell-Based Therapy, GERON (Jan. 23, 2009),
http://www.geron.com/media/pressview.aspx?id 1148. Field Code Changed
8 Stem Cell Reseach [sic], supra note 73.
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systematic investigation."7 In the government's memorandum to
the U.S. Court of Appeals in support of a stay of the preliminary
injunction, defendants' counsel contests the overly-broad
definition of the word "research" in favor of a more narrow
definition or, in the alternative, reading the word "research" in
context of the surrounding text." While such textualism is
common practice in the judicial arena, it gives the appearance of
splitting hairs over something necessarily subjective and relatively
insignificant. 9
Potential clinical treatments involving stem cell research can
take years to develop and serious commitment on the part of
researchers in the field.9 o Given the social and political debate
surrounding this issue and the high stakes of the research involved,
it is probable that the loser at the appellate level will try to take the
issue to the Supreme Court. This will likely be a long and drawn
out process. To let this issue play out in the courts where opposing
counsel will argue over the scope of the word "research" will result
in a loss of confidence in the federal government.
Congress has had the opportunity to clarify the language of the
Dickey-Wicker Amendment every fiscal year for over a decade,
but has failed to do so in favor of permitting the long-standing
agency interpretation. The Rabb memorandum presented a way
for HHS and the NIH to fund critical research in the face of an
explicit appropriations limitation. However, an agency's adoption
of a legal opinion does not have the same force as direct
congressional action. At this point, only the courts or the
8 Sherley v. Sebelius, 704 F. Supp. 2d 63, 70 (D.D.C. 2010)
88 Memorandum in Support of Defendants' Motion to Dismiss, and in
Opposition to Plaintiffs' Motion for Preliminary Injunction at 3 1-32, Sherley v.
Sebelius, 704 F. Supp. 2d 63 (D.D.C. 2010) (No. 1:09-cv-01575-RCL).
89 "Textualism is a formalist theory of statutory interpretation which holds that
a statute's ordinary meaning should govern its interpretation, as opposed to
inquiries into non-textual sources such as the intention of the legislature in
passing the law, the problem it was intended to remedy, or substantive questions
of the justice and rectitude of the law." Extended Definition: Textualism,
WEBSTERS ONUNE DICTIONARY, http://www.websters-online-dictionary.org/
definitions/textualism (last visited Sept. 27, 2010).
90 See Hearing, supra note 20, at 8 (statement of Dr. Francis Collins, Director,
National Institutes of Health).
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legislature have the authority to decide if the new Guidelines can
be implemented. As a matter of policy, this is more appropriately
settled by the legislature where it can be debated and viewed as a
whole issue rather than as a matter of statutory interpretation.
C. Congress Should Pass a Comprehensive Stem Cell Bill
In addition to narrowing the Dickey-Wicker Amendment,
Congress should pass a bill that will expressly state its intentions
regarding embryonic stem cell research. Preferably, such a bill
will codify President Obama's executive order and open the door
to a transparent set of rules that will regulate future hESC research.
There is already a bill in Committee that would accomplish this
objective. The Stem Cell Research Advancement Act of 200991
was introduced to the House of Representatives on March 10,
2010, one year after President Obama's executive order was
signed. 92
On September 13, 2010, a companion bill was introduced to
the Senate, similarly titled the Stem Cell Research Advancement
Act of 2010.93 These bills call for the support of stem cell research,
explicitly including embryonic stem cell research where the stem
cells were derived from excess embryos donated from in vitro
fertilization clinics.94  Additionally, the bills require that a
consultation with the donors be conducted to ensure that the
embryos would otherwise be discarded and those individuals
donating their embryos provide written, informed consent without
receiving financial or other inducement. 95 The legislation would
require the NIH to maintain guidelines and update them every
three years or as "scientifically warranted." 96 These provisions, if
91 Stem Cell Research Advancement Act of 2009, H.R. 4808, 111th Cong.
(2010).
92 Stem Cell Research: Embryonic Stem Cell Research Legislation Introduced
to Codify Obama Executive Order, Biotech Watch Online (BNA) (Mar. 12,
2010).
93 Stem Cell Research Advancement Act of 2010,. S. 3766, 111th Congress,
(2010).
94 See id § 498(E); see also H.R. 4808, § 498(D).
95 S. 3766 § 498(E); H.R. 4808, § 498(D).
96 See S. 3766, § 498(F); see also H.R. 4808, § 498(E).
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enacted, would provide a codification of President Obama's
executive order.
The only notable difference between the bills is that the more
recent Senate bill explicitly states that this act shall not supersede
section 509 of the most recent HHS appropriations bill.97 This is a
direct reference to the language of the Dickey-Wicker Amendment
restricting funding of research that results in the destruction of
embryos. Both the House and Senate bills would amend the Public
Health Service Act98 "[n]otwithstanding any other provision of
law," so technically the additional language found in the Senate
bill would make no applicable difference. 99 However, the new
language does evidence the Senate's intent to comply with the
Dickey-Wicker Amendment. In order for this bill to have its
intended effect, the appellate courts will have to uphold the Rabb
interpretation of the Dickey-Wicker Amendment.o" The Rabb
interpretation is essentially a legal workaround that should not
serve as a permanent solution, but rather should have worked as
merely a stopgap until Congress could act.
Congress should make it a priority to get this legislation
through committee and onto the floor for debate. Also, those
representatives who support stem cell research should make it a
goal to amend the Dickey-Wicker Amendment to allow for
research on pre-implantation stage embryos obtained under the
ethical boundaries set forth in the Act. The Bush Administration
succeeded in delaying important research, and President Obama
tried to reverse the policy through an executive order.
Unfortunately, with the recent court ruling, the Obama
97 S. 3766, § 498(E) (stating "[n]otwithstanding any other provision of law,
including section 509 of division D of the Consolidated Appropriations Act,
2010 or any substantially similar provision in any previous or subsequent
Departments of Labor, Health and Human Services, and Education, and Related
Agencies Appropriations Act . .").
98 Public Health Service Act, 42 U.S.C. § 289 (2006).
99 S. 3766, § 498(E); H.R. 4808, § 498(D).
100 That is the Court of Appeals would have to find that human embryonic
stem cells are not the same as human embryos for the purpose of medical
research. See Memorandum from HHS Gen. Counsel Harriet Rabb to Harold
Varmus, Dir., NIH (Jan. 15, 1999).
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Administration's effort may fail. Relying on the appellate process
to vindicate the agency interpretation of the Amendment is a
gamble. The more appropriate solution is to have our elected
representatives pass legislation that will reassure the research
community of continued funding.
V. CONCLUSION
The decision in Sherley v. Sebelius is a setback for potentially
life-saving medical research. Public funding of embryonic stem
cell research benefits the public welfare. Therefore, Congress
should take action that will explicitly support this type of research.
In this economy, the absence of public funding could truly hinder
further medical breakthroughs involving human embryonic stem
cells. Judge Lamberth rested his holding in the case on the
language of the Dickey-Wicker Amendment. The Amendment,
which was added to the appropriations bill before embryonic stem
cells could be isolated and grown in culture, is outdated and should
be narrowed to allow for research that has been implicitly
approved by Congress and the Executive Branch for over ten
years. Furthermore, Congress should finally pass a stem cell bill
that reflects the executive order issued by President Obama in
2009. Scientists still have a lot to learn from studying human
embryonic stem cells, and we should allow those scientists the
opportunity to decide which cells to study and to what extent."'
American scientists should have the best opportunity to follow
through on the promising research they have been conducting and
an incentive to continue with progressive research. Otherwise, the
denial of federal funds could mean the denial of hope for many
Americans struggling with debilitating diseases.
101 See Hearing, supra note 20, at 2 (statement of Dr. George Q. Daley, M.D.,
PhD).
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